An interventional study of Study to evaluate a Respiratory Monitoring System (RMS) with a Tracheal Sound Sensor (TSS) for detecting and predicting opioid induced respiratory Depression (OIRD). in Respiration Disorders, sponsored by Thomas Jefferson University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Respiration Disorders with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Respiration Disorders · United States.
Among the 71 studies in Respiration Disorders with a site in United States, this one is the 19th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2026, is one of 25 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 69th registered.
359 studies on the registry are indexed under Respiration Disorders; 64 are open to participants now.
Browse Respiration Disorders studies →15 of the 71 studies in Respiration Disorders with a site in United States are open now. Recruiting first, the newest first:
Windward Bio · Sites in United States, Argentina
Ages 40–80
Quantec Ltd · Sites in United States
Ages 60+ · Healthy volunteers
Geisinger Clinic · Sites in United States
Ages 65–100
University of Florida · Sites in United States
Ages 1 hrs–3 days
University of Louisville · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Respiration Disorders studies recruiting now, 27 (60%) set no upper age limit and 13 (29%) stop at 75 or younger; 15 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 5 · Phase 4 3
First in 1997; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 69 across 216 interventional studies indexed under Respiration Disorders.
Median enrollment 86 across the 48 interventional studies, 450 across the 23 observational. Of the 45 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 71 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 1 study filed under Respiration Disorders — fewer than ten, so there is no comparison to draw.
5 of the studies in Respiration Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217197Thomas Jefferson UniversityRespiratory Monitoring System That Detects & Predicts OIRD | 2026-11-30 |
| NCT06495021Geisinger ClinicHow OMT Benefits Newly Diagnosed Patients With Respiratory Illness When Given Alongside Other Standard Care. | 2026-12-31 |
| NCT05527652University of MichiganSelf-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia | 2027-05 |
| NCT04179981VA Office of Research and DevelopmentImpact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome) | 2027-09-30 |
| NCT03319446BioFire Diagnostics, LLCCollection of Anonymized Samples | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 71 studies in Respiration Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the ability of the Respiratory Monitoring System (RMS) to detect and predict opioid induced respiratory depression (OIRD) in post-operative surgical patients managed with opioid medications. The ability of the RMS to detect OIRD will be compared to the detection of OIRD using a commercial capnometer, pulse oximeter, airflow monitor, and breathing volume monitor .
We hypothesize the RMS will detect the onset and progression of a true OIRD event with high sensitivity, specificity, positive predictive value, and negative predictive value. A true OIRD event will be determined by the reference device trend data.
RTM Vital Signs, LLC is developing a Respiratory Monitoring System (RMS) that consists of a wearable Trachea Sound Sensor (TSS) and a software application that measures the sounds of air flow within the trachea during inhalation and exhalation and cardiovascular sounds. The sounds of airflow in the trachea are used to continuously monitor a patient's respiratory rate (RR), relative tidal volume (TV), relative minute ventilation (MV), pattern of breathing, duration of apnea in a healthcare setting. The cardiovascular sounds are used to continuously monitor pulse rate and PR variability.
Once commercialized, clinicians will observe the RMS trend data on a smart phone, bedside display, or electronic medical record to determine whether the patient is breathing within their normal range, breathing more than their normal range (hyperventilation), breathing less than their normal range (hypoventilation), or not breathing (apnea). Real-time alerts and alarms will be based upon trends in a patient's rate and depth of breathing, number and duration of apnea events, RTM's Risk-Index-Score, and RTM's machine learning/artificial intelligence methods.
TJU research personnel will be trained by RTM personnel to ensure all questions related to the proper use of the device and study methods are addressed prior to application and use.
Subject Screening:
Patients scheduled for surgery at Thomas Jefferson University Hospital will be screened for recruitment and enrollment. Potential study subjects will be contacted by a research coordinator for pre-screening, screening for inclusion/exclusion criteria, and initial informed consent. The following assessments will be performed as part of the screening and eligibility evaluation:
Informed Consent:
Subjects interested in participating in the research study after the initial informed consent discussion will be contacted by a study investigator. An investigator will complete the informal consent process (in-person or virtual). The subject will receive a signed copy of the consent document.
Subject Enrollment:
Subjects will be considered enrolled upon consent. If consent is obtained prior to presenting to TJUH, the subject will be re-evaluated for all inclusion and exclusion criteria. A urine pregnancy test will be performed based upon age and LNMP. If any criteria are not met the subject will be excluded from the study without testing. Any subjects that are withdrawn prior to attaching the RMS and data collection will not count against the total evaluated population.
Data Requirements:
Data regarding demographics, medical/surgical history, current medications, current symptoms, laboratory results, and inclusion / exclusion criteria will be captured prior to commencing study related procedures.
A summary of the study data for analysis is listed below:
6. Patient data from the TJUH electronic medical record, including date/time/dose of medications delivered, laboratory results, imaging results, medical history, physical examination, diagnostic codes, hospital length of stay, any adverse events, clinical outcomes in the hospital, and clinical outcomes 30 days and 60 days after hospital discharge.
Some study data will be recorded on paper source documents and some data will be recorded on a password protected/encrypted computer and stored in a HIPPA compliant Cloud account.
General Study Procedure Protocol-
Data Collection:
Blinded data will be collected/recorded by research personnel at Thomas Jefferson University Hospital located in center city Philadelphia. RMS breathing data and reference breathing data will be recorded upon admission to the hospital for approximately 15 minutes (baseline), in the PACU for a maximum of 24 hours, and on the general wards, ICU, or intermediate ICU for a maximum of 24 hours.
Baseline Procedure:
Upon admission to the hospital, the TSS's acoustic sensor head (containing two microphones) will be adhered to the study subject's neck above the proximal trachea (midline within the sternal notch or side of the neck) with medical adhesive tape. The sensor's body will be adhered to the skin of the chest wall with medical adhesive tape. RMS data will be transmitted via Bluetooth low energy to a software program on an adjacent tablet computer for recording. RMS data will be recorded with the patient breathing normal RR and TV for approximately 15 minutes. The subject may be asked to breath with a deeper depth of breathing and a more shallow depth of breathing during the baseline recording procedure.
In addition, breathing data will be recorded using a reference volume monitor (ExSpiron 2Xi) and a reference airflow monitor, carbon dioxide monitor, and oxygen saturation monitor (Hamilton C-1 ventilator pneumotach, capnometer, and pulse oximeter). The ExSpiron 2Xi uses an electrical impedance method with electrodes adhered to the chest wall for measuring RR, relative TV and relative MV. The Hamilton uses an airflow sensor, a capnometer, and a pulse oximeter to measure PR, oxygen saturation, RR, apnea duration, and carbon dioxide concentration.
All devices will be removed upon completion of the 15 minute baseline procedure.
Data Collection in the Post-Anesthesia Care Unit (PACU):
TJUH nurses and physicians will manage post-operative surgical patients using routine standard-of-care methods for pain control. Long-acting opioids, short-acting opioids, and non-opioid analgesics will be routinely delivered by PACU nurses to manage a patient's post-operative pain.
Blinded RMS breathing data and time-synced reference breathing data (ExSpiron 2Xi volume data) will be recorded once situated in the PACU. The Medtronic Capnostream's capnometer nasal cannula and pulse oximeter finger probe will also be attached to the patient. Data will be recorded for a maximum of 24 hours while PACU nurses manage the patient's post-operative pain using routine standard-of-care methods.
Data Collection on the General Wards, ICU, or intermediate ICU:
Upon leaving the PACU, RMS breathing data and Medtronic Capnostream breathing data will be recorded on the hospital general wards, ICU, and/or intermediate ICU for a maximum of 24 hours. RMS data will be transmitted via Bluetooth low energy to an adjacent tablet computer for recording.
Time-synced Capnostream capnometer reference data (using a nasal cannula) and pulse oximeter reference data (using a finger probe) will be continuously recorded for a maximum of 24 hours. Time-synced ExSpiron reference data (using electrode pads on chest wall) will be recorded for a maximum of 24 hours.
All research data will be blinded (clinicians will not have access to any research data). TJUH nurses will manage their post-operative surgical patients using routine standard-of-care methods for pain control. Long-acting opioids, short-acting opioids, and non-opioid analgesics will be routinely delivered by ward nurses to manage a patient's post-operative pain.
The TSS, Capnostream nasal cannula, and ExSpiron 2Xi electrode pad set will be removed after a maximum of 24 hours of blinded data collection. The ExSpiron pad set may be removed prior to the 24 hours if requested by the patient.
The TSS will be removed and the skin examined for any evidence of irritation, inflammation, or injury. The area of TSS attachment may be photographed. Recorded RMS data, reference breathing data, and de-identified EMR data will be uploaded to an encrypted HIPPA compliance data base.
Data Analysis:
Recorded Capnostream trend data will be analyzed by experienced clinicians in relationship to medication delivery to identify true OIRD events by 2 methods:. One method of data analysis will use the PRODIGY definition of a true OIRD event: 1) RR less than 5 breaths/minute for greater than 3 minutes, 2) hemoglobin oxygen saturation less than 85% for greater than 3 minutes, 3) a period of apnea lasting greater than 30 seconds, 4) and end-tidal carbon dioxide concentration less than 15 mm Hg or greater than 60 mm Hg, or 5) treatment with naloxone to reverse OIRD. The PRODIGY study observed a 46% incidence of OIRD in hospitalized patients managed with parenteral opioids using the above definition. Another method of data analysis will use RTM's definition of a true OIRD event: 1) RR less than 8 breaths/minute for greater than 3 minutes, 2) hemoglobin oxygen saturation less than 90% for greater than 3 minutes, 3) a period of apnea lasting greater than 15 seconds, 4) an end-tidal carbon dioxide concentration less than 20 mm Hg or greater than 50 mm Hg, or 5) treatment with naloxone to reverse OIRD. Experienced clinicians will adjudicate the RMS data and reference breathing data to identify trend data that is missing, uninterpretable, and/or out-of-range.
The RMS data (RR, relative TV, relative MV, apnea duration, PR) will also be compared/correlated with the Hamilton reference data (RR, TV, MV, apnea duration, PR, carbon dioxide concentration) and the ExSpiron 2Xi reference data (RR, relative TV, relative MV) to determine the accuracy of measurement. The correlation will be determined using mean difference, bias, precision, mean-absolute relative difference, standard deviation, and Bland-Altman plots.
Other Data Collection:
A research coordinator will contact each patient 1 to 3 days after completion of data collection and approximately 30 days and 60 days later to document any adverse events and clinical outcomes. Investigators will review the EPIC electronic medical record in detail to determine time/dose of opioid, sedative, anesthetic, and other medication delivery; and to identify clinical signs/symptoms of clinical deterioration with a focus on OIRD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a non-significant risk clinical trial in 120 patients that are undergoing a surgical procedure that routinely utilizes parenteral and oral opioids for post-operative pain control. We plan to recruit and study a similar number of male/female patients with a range of ages and BMI.
Device: Study to evaluate a Respiratory Monitoring System (RMS) with a Tracheal Sound Sensor (TSS) for detecting and predicting opioid induced respiratory Depression (OIRD).
Expert clinicians will evaluate the ability of the RMS sensor and diagnostic algorithms to detect and predict true OIRD events in post-operative patients routinely managed with opioid medications. Expert clinicians will adjudicate detailed reference data and EMR data to identify a true OIRD event. The definition of a true OIRD event will be based upon the PRODIGY Study definition and RTM definition of a true event. Performance of the RMS will be based upon the sensitivity, specificity, positive predictive value, and negative predictive value for detecting true OIRD events.
Evaluate RMS Trend Data Prior to Each True OIRD Event to Determine the Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value for Detecting and Predicting a True OIRD Event.
Evaluate the recorded RMS trend data using a variety of analytical methods (pattern recognition, Risk-Index-Score, machine learning/artificial intelligence) to determine the sensitivity, specificity, positive predictive value, and negative predictive value for detecting a true OIRD event in post-operative surgical patients being managed with opioid medications for pain control.
Time frame: From placement of the TSS and reference devices to device removal. A maximum of 24 hours of RMS and mask/pneumotach data in the PACU and a maximum of 24 hours of RMS and reference breathing data on the general wards, ICU, or intermediate ICU.
Correlate RMS breathing data to reference breathing data to determine accuracy and precision of measurement.
Correlate the RMS breathing data to time-synced Hamilton C-1 ventilator reference data (airflow during inhalation/exhalation, RR, TV, MV, apnea duration, PR, oxygen saturation, carbon dioxide concentration), ExSpiron 2Xi reference data (RR, relative TV, relative MV), and Capnostream reference data (RR, duration of apnea, carbon dioxide concentration, PR, and oxygen saturation) recordings to calculate accuracy and precision.
Time frame: Baseline -RMS, Hamilton and ExSpiron reference data (15 min max). PACU- RMS, Hamilton , ExSpiron, and Capnostream reference data (90 min max for mask/pnuemotach). Hospital Wards, ICU, iICU- RMS, ExSpiron and Capnostream (reference data 24 hours max).
RMS Safety Endpoint
The TSS will be removed from the skin of the neck after 26+ hours of wear-time. A clinician will perform a physical examination of the skin site approximately 10 minutes after removal of the TSS to evaluate for erythema, induration, or any injury of the epidermis or dermis. Research staff will document any allergic reaction, skin irritation, or injury that required premature removal of the TSS or medical intervention.
Time frame: From TSS adhesion on the neck to removal of the TSS for 26+ hours of wear-time.
Plan to share: Undecided — Summary data will be included in peer publications and patent applications. Individual patient data may be included in peer publications but may not be shared with other research scientists until patent applications are submitted and IP secured.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.
Of 91 non-industry interventional studies with no phase under Respiration Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 10 months is below that.
Counting every sponsor, half of 111 studies reached it within 18 months; a quarter within 7 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.